Ignite Creation Date:
2024-05-05 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00519870
Status:
COMPLETED
Last Update Posted:
2007-08-23
First Post:
2007-08-22
Brief Title:
Losartan Therapy in Pulmonary Hypertension
Sponsor:
Baskent University
Organization:
Baskent University
Study Overview
Official Title:
Losartan Decreases Pulmonary Artery Pressure and Improves Exercise Capacity in Patients With Pulmonary Hypertension
Status:
COMPLETED
Status Verified Date:
2007-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In addition to being effective vasodilators angiotensin-converting enzyme inhibitors ACEIs and angiotensin receptor blockers ARBs exert neurohumoral inhibitory actions such as the inhibition of vascular remodeling and smooth muscle cell proliferation and the amelioration of endothelial dysfunction These beneficial effects render those agents appropriate for use in the treatment of pulmonary hypertension However data regarding the use of ACEIs or ARBs in the treatment of PHT are limited In this study efficacy of an ARB losartan was compared with those of the calcium channel blocker nifedipine in the treatment of pulmonary hypertension using echocardiographic 6-minute walk test 6MWT cardiopulmonary exercise test and endothelin-1 levelsLosartan is as effective as nifedipine for reducing Doppler echocardiographically measured PAP and improving exercise capacity on 6MWT and CPET However the short-term use of losartan or nifedipine had no statistically significant effect on endothelin-1 levels in patients with PHT
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None